This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Leading Biotechnology Company Renews Multi-Million Dollar Enterprise Agreement For OmniComm Systems' TrialMaster EDC Solution

FORT LAUDERDALE, Fla., Feb. 5, 2013 (GLOBE NEWSWIRE) -- OmniComm Systems, Inc. (OTCBB:OMCM), one of the fastest growing companies in the Electronic Data Capture (EDC) marketplace, today announced the renewal of an Enterprise Agreement to deploy TrialMaster®, their Electronic Data Capture (EDC) suite, with one of the largest biotechnology companies in the U.S. This two year agreement is expected to generate over $2M in revenue during the support of multiple clinical trial programs.

"We are honored that this leading biotech client has again chosen to partner with OmniComm for their clinical research needs," commented Stephen Johnson, OmniComm's President & COO. "This is a strong testament to the quality of the products and services that OmniComm delivers, and we look forward to continuing this fruitful partnership."

This contract renewal is the latest in a string of new and recurring business with biotech clients. OmniComm attributes its success to many new innovative functions and features across its multiple product lines, and to its strong customer service and support programs.

"Biotechnology companies are at the forefront of medical research, and often need very sophisticated features to implement their study designs," commented Keith Howells, OmniComm's Senior Vice President of Development. "TrialMaster includes features such as guided data entry, risk-based monitoring and out-of-the-box generation of submission-ready datasets, which are very attractive to this industry. We are proud of this latest endorsement of our innovation strategy."

About OmniComm

OmniComm Systems, Inc. ( www.OmniComm.com ) provides customer-driven Internet solutions to pharmaceutical, biotechnology, and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.

The OmniComm Systems Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13414

Safe Harbor Disclaimer

Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

CONTACT: Bev Hudson
         SVP of Business Development,
         OmniComm Systems, Inc.
         954-473-1254
         bhudson@omnicomm.com

company logo

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs